I-Corps: Three Dimensional Bio-Printing of Human Tissues

I-Corps项目更广泛的影响/商业潜力是增加具有成本效益的自动化3D生物打印平台的可用性，该平台能够原位重建生物组织。现有的生物打印技术是有限的，只有拥有大量资源的机构才能使用，因此限制了它给学术和非学术部门带来的潜力。在一个又一个行业中，由于不准确的药物测试和使用动物模型时的翻译差距错误，许多后期试验可能会失败。作为替代方案，在进行动物模型测试之前，对3D打印人体组织模型进行测试可以降低成本，这是一个有价值的中间步骤。其次，3D生物打印在制药公司的应用将提高药物筛选的吞吐量。第三，学术界的研究人员可以进一步推进3D生物材料工程。第四，随着教育部门向下一代科学标准课程迈进，生物打印机作为课堂上动手学习的创新工具具有巨大潜力。教育工作者可以利用3D生物打印作为一种强大的教学工具来培训和授权下一代科学家从事他们的研究。最终，该项目旨在为全世界的研究人员和学生创造积极的影响并改善技术获取。这个I-Corps项目基于一项核心技术，该技术允许研究人员打印各种组织结构。这种生物打印机能够利用人类成纤维细胞和角质形成细胞重建可存活的皮肤结构。这个项目吗?该公司的最小可行产品（MVP）是一种生物打印机，采用三种不同的技术，具有多模块系统。该产品中使用的技术可以在3D高保真支架的构建过程中按需定制生物材料，并将细胞精确放置到微米级。总之，这些模块的组合创造了一个多功能的产品，具有广泛的应用。这一发展将提高生物打印技术的可及性，并将进一步推进组织工程。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this I-Corps project is to increase the availability of cost-effective automated 3D bioprinting platforms capable of reconstructing biological tissue in situ. Existing bioprinting technology is limited and only available to institutions with vast amounts of resources, therefore limiting the potential it can bring to both academic and non-academic sectors. In industry, industry, many late stage trials can fail due to inaccurate drug testing and errors in the translational gap when using animal models. As an alternative, testing on 3D printed human tissue models could reduce costs as a valuable intermediate step before proceeding to animal model testing. Second, 3D bioprinting applications in pharmaceutical companies will increase throughput in drug screening. Third, researchers in academia can further advances in 3D biomaterial engineering. Fourth, with the education sector moving towards a Next Generation Science Standards curriculum, bioprinters have immense potential as an innovative tool for hands-on learning in the classroom. Educators can utilize 3D bioprinting as a powerful teaching tool to train and empower the next generation of scientists in pursuing their research. Ultimately, this project aims to create a positive impact and improve technological access worldwide for researchers and students alike.This I-Corps project is based on a core technology that allows researchers to print various tissue constructs. This bioprinter is able to reconstruct a viable skin construct using human fibroblasts and keratinocytes. The project?s minimum viable product (MVP) is a bioprinter with a multi-modular system using three different technologies. The technologies used in this product enable on-demand biomaterial customization during the construction of a 3D high-fidelity scaffold and precision placement of cells down to the micron level. Together, the combination of these modules creates a versatile product that has broad applications. This development will improve accessibility of the bioprinting technology and will further advancements in tissue engineering.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.